• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice New Year’s Special | Brian DeChristopher

MassDevice New Year’s Special | Brian DeChristopher

December 27, 2010 By MassDevice staff

Chordant Capital logo

Brian DeChristopher
Managing Partner, Chordant Capital (photo not available)

Brian DeChristopher, managing partner at Chordant Capital Partners LLC, has stints as an analyst at Putnam Investments and Arthur D. Little under his belt. He spent a good chunk of that time researching firms in the device industry, but that’s not his most important qualification for us here at MassDevice — DeChristopher also went to high school with co-founder and editor Brad Perriello.

Though they lost touch after those halcyon days, Perriello and DeChristopher recently re-connected via an investor presentation by Abiomed Inc. (NSDQ:ABMD). We asked DeChristopher to peg what’s hot (and what’s not) from the perspective of a potential device investor. Here’s what he came up with:

In terms of what is hot from the perspective of an investor, I’ll focus here on the trends and competitive interest in those trends.

MassDevice New Year’s Special P/review

  • P/review: Introduction
  • P/review: Paul LaViolette
  • P/review: Stephen Ubl
  • P/review: David Lucchino
  • P/review: Euan Thomson
  • P/review: Brian DeChristopher
  • P/review: Christopher Delporte
  • P/review: Don Hardison
  • P/review: Brent Hudson

  • P/review: Hamid Tatabaie
  • P/review: Patrick Dentinger
  • P/review: Nancy Briefs
  • P/review: Brian Concannon
  • P/review: Ryan Howard
  • P/review: Ed Berger
  • P/review: Top stories of 2010

What was hot:

  • Percutaneous Valves
  • Vascular Imaging – FFR and IVUS
  • Structural Heart
  • Endo- and Neuro-vascular Devices
  • LVAD’s
  • Second-generation Insulin Pumps and Continuous Glucose Monitors

What was not hot:

  • Ortho & Spine
  • Stents

Looking forward, I’m focused on areas that either improve efficiency or improve appropriate device utilization. A prime example of this is intravascular ultrasound (IVUS), fractional flow reserve (FFR) and the emergence of optical coherence tomography (OCT). The government is investigating stent over-utilization, a problem these technologies help solve by better locating precisely where and how stents should be placed and providing hard data for physicians to use to justify the implant in the first place.

Given the pricing and utilization pressures on more developed device markets (stents, ICDs, orthopedics and spine), the larger companies in these areas will remain very focused on expanding beyond these markets. A resurgent and successful Boston Scientific (NYSE:BSX) is very dependent on this strategy, as is Medtronic (NYSE:MDT), which will likely go through a larger restructuring with a new CEO. I don’t expect spine companies to buck the broader orthopedic trends and I also don’t expect them to be bailed out via acquisition — the Medtronic/Kyphon deal seriously damaged that route.

Any areas with a potential target on them related to comparative effectiveness are less interesting to me. An example is robotic surgery. The technology has done extremely well in prostate and parts of the hysterectomy market. Adoption could hit a wall with the combined forces of EU austerity, low robot utilization and questions about cost versus differentiated clinical outcomes beyond the currently served markets.

Second-generation insulin pumps and continuous glucose monitors should continue to advance in the market. They’re generally a low-ticket item that improves compliance, outcomes and disease management/progression and have taken hold in younger patients — a very positive sign.

Percutaneous valves will clearly remain hot. The larger question is how competitive the market will become and how far the technology can penetrate the core valve market. Because of the potential market size and solid advances to date, I expect further competitive developments in this area and intense focus from many companies and entrants.

I’m lukewarm on left ventricular assist devices (LVAD). The market potential on paper is significant and the data are positive. However, beyond the initial bolus of patients that were implanted post-FDA approval of Thoratec’s (NSDQ:THOR) destination therapy indication, I’m concerned about how deep the market really is and how much effort, time and resources it will take to develop. There are some who believe a fully implantable LVAD will be needed to significantly increase market penetration, which is years away. Secondarily, the cost-per-quality-adjusted-year is trending down, but is still significantly higher (~$200,000) than other, very expensive therapies like ICD/CRTDs or even dialysis. In absolute terms, the market is small and not likely an immediate target for comparative effectiveness studies.

I’d like to see the industry embrace some of the change on the regulatory front — build cost-effectiveness into their business models from the start. Healthcare has been an industry in which price has been stable-to-up on similar items but generally has gone up with newly introduced products. Most other industries see lower prices over time with improved quality because of innovation. The winds have shifted. Hopefully, that will yield innovation as well as attention to cost-effectiveness, as an important measure of the strength of a business model or idea.

Filed Under: Uncategorized Tagged With: Chordant Capital Partners LLC

In case you missed it

  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid
  • Baxter expects sales growth momentum through 2025
  • Vivera picks up new patent for electronic dose-controlled drug delivery devices
  • Stryker launches dynamic compression system for foot, ankle applications
  • Entegris opens Life Sciences Technology Center in Massachusetts
  • Glucose monitor maker Know Labs expands leadership team
  • inHeart wins FDA clearance for 3D cardiac modeling software
  • How Glytec is advancing insulin management in the hospital
  • Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
  • FDA clears RapidAI’s pulmonary embolism triage platform
  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive

RSS From Medical Design & Outsourcing

  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maple Grove, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]
  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS